Making an Impact Today: Building the Road to a Cure Through Innovation and Hope

Why Guess When You Can Know?

With over two billion monthly users across more than 220 countries, Google Maps has become an indispensable navigation tool, offering real-time updates on locations, routes, and road conditions. Now, imagine applying that same precision and insight to cancer research as Google Maps has to navigation.

Researchers from the Saskatchewan Cancer Agency and the University of Saskatchewan are building a "Cancer Map"—an innovative tool designed to uncover the complex networks of genetic interactions within cancer cells. This groundbreaking research aims to identify new vulnerabilities in cancer and improve targeted treatments, transforming how we fight the disease.

A Commitment to Progress and Excellence

Dr. Franco J. Vizeacoumar, senior scientist at the Saskatchewan Cancer Agency and an associate professor of oncology at the University of Saskatchewan, is at the forefront of this research. Inspired by a passion for making a difference in people's lives, Dr. Vizeacoumar and his team are working tirelessly to understand cancer at its genetic level and develop strategies to outsmart it based on patient-specific genetic profiles.

Image

His research on cancer genomic approaches has gained national recognition and paved the way for his recent speaking engagement at TEDxUniversityofSaskatchewan on February 2, 2025. Dr. Vizeacoumar's talk, "Building a Cancer Map: The Road to a Cure," explores how cancer cells rely on specific genetic pathways to survive and grow. By studying these pathways, he and his team aim to disrupt them, refining their approach to create precise and effective personalized, targeted therapies—even for the most aggressive cancers. "The road to a cure is about tackling cancer head-on and outsmarting it with innovative genetic approaches. It’s like playing chess with cancer—figuring out its moves before it can make its next one. And while we may get defeated sometimes, each move teaches us something valuable, bringing us closer to victory," he explains.

Dr. Vizeacoumar, along with Dr. Andrew Freywald, an expert in animal models of cancer, and Dr. Frederick Vizeacoumar, who specializes in bioinformatics and machine learning—are leveraging cutting-edge methods like gene editing and genomics to identify drug targets and develop personalized, effective cancer treatments. 

A Game-Changer in Cancer Research

Dr. Vizeacoumar's research focuses on enzymes stabilizing the active genome in approximately 85 percent of cancers. This means his discoveries could lead to treatments that benefit a wide range of patients.

After earning his PhD at the University of Alberta, he pursued postdoctoral training in Systems Biology at the University of Toronto. With over 12 years of dedication to solving complex cancer research challenges at the Saskatchewan Cancer Agency, he continues to push the boundaries of innovation. Their work began with simple tools like spanners and screwdrivers, assembling instruments from discarded equipment; due to the challenge of securing funding and the ongoing need for financial support, this project has evolved into a groundbreaking initiative. "We made it work because science doesn't wait," he said, recalling the early years and their willpower to push work forward on a tight budget. They've made remarkable progress to this point.

Dr. Vizeacoumar and his team are committed to advancing their work and bringing hope to cancer patients.

Cancer affects everyone in some way, and for Dr. Vizeacoumar, it is personal. The loss of his in-laws to cancer fuels his determination to make a difference. Having witnessed the devastating impact of the disease firsthand, his commitment to research is unwavering.

He and his team have been steadily building a comprehensive' Cancer Map.' Day by day, step by step, the work is paving the way for a future where cancer is no longer a life-threatening diagnosis.

"With the right map, we may just find our way to a cure," he says.

A Future of Hope

Thanks to innovative cancer research like this, we can look ahead with optimism—hope is on its way.

Learn more about Dr. Vizeacoumar's work and background here.